卡培他滨和替莫唑胺方案在神经内分泌肿瘤中的疗效：来自土耳其肿瘤学团队的数据。
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.
发表日期：2023 Sep 07
作者：
Çağlar Ünal, Abdulmunir Azizy, Senem Karabulut, Didem Taştekin, Arif Akyıldız, Serkan Yaşar, Şuayib Yalçın, Eyüp Çoban, Türkkan Evrensel, Ziya Kalkan, Zeynep Oruç, Sümeyra Derin, Zeynep Hande Turna, Doğan Bayram, Fahriye Tuğba Köş, Mehmet Ali Nihat Şendur, Nadiye Sever, Özlem Ercelep, Mustafa Seyyar, Umut Kefeli, Kazım Uygun, Melike Özçelik, Sercan Ön, Ulus Ali Şanlı, Kübra Canaslan, İlkay Tuba Ünek, Kadriye Bir Yücel, Nuriye Özdemir, Ozan Yazıcı, Halil Göksel Güzel, Derya Kıvrak Salim, Sema Sezgin Göksu, Ali Murat Tatlı, Çetin Ordu, Oğuzhan Selvi, Abdullah Sakin, Mehmet Emin Büyükbayram, Bengü Dursun, Yüksel Ürün, Hacı Arak, Gözde Ağdaş, Muzaffer Uğraklı, Engin Hendem, Melek Karakurt Eryılmaz, Burak Bilgin, Atakan Topçu, Melih Şimşek, Mahmut Büyükşimşek, Büşra Akay, Gülçin Şahingöz Erdal, Fatih Karataş, Özkan Alan, Melek Çağlayan, Fatma Akdağ Kahvecioğlu, Ayşe Demirci, Nail Paksoy, Bülent Çetin, Mahmut Gümüş, Naziye Ak, Yasemin Aydınalp, Semra Paydaş, Deniz Can Güven, Saadettin Kılıçkap, Sezer Sağlam
来源：
MEDICINE & SCIENCE IN SPORTS & EXERCISE
摘要：
本研究旨在报告不同治疗线路下曲妥珠单抗加替莫唑胺（CAPTEM）对转移性神经内分泌肿瘤（NETs）患者的疗效和安全性。我们进行了一项多中心回顾性研究，分析了土耳其各个地区34家不同医院2010年至2022年期间308名接受CAPTEM治疗的转移性NETs患者的数据。中位随访时间为41.0个月（范围：1.7-212.1），中位年龄为53岁（范围：22-79）。我们在整个患者队列中的结果显示，中位无进展生存期（PFS）为10.6个月，中位总生存期（OS）为60.4个月。一线CAPTEM治疗表现更有效，中位PFS为16.1个月，中位OS为105.8个月（一线、二线和≥三线分别的中位PFS分别为16.1、7.9和9.6个月，P = 0.01；相应的中位OS值分别为105.8、47.2和24.1个月，P = 0.003）。在ORR方面，一线治疗再次表现更好，结果显示ORR分别为54.7%、33.3%和30.0%（P < 0.001）。3-4级副作用仅发生在22.5%的患者中，导致中止率为9.5%。尽管基于治疗线路的结果有差异，但我们在副作用方面并未观察到一线和后续治疗之间的显著差异。接受一线CAPTEM治疗的患者取得了显著优越的治疗结果，突显了其作为转移性NET患者的有效治疗策略的潜力。© 作者们 2023年。由牛津大学出版。
This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs).We conducted a multicenter retrospective study analyzing the data of 308 patients with metastatic NETs treated with CAPTEM between 2010 and 2022 in 34 different hospitals across various regions of Turkey.The median follow-up time was 41.0 months (range: 1.7-212.1), and the median age was 53 years (range: 22-79). Our results across the entire patient cohort showed a median progression-free survival (PFS) of 10.6 months and a median overall survival (OS) of 60.4 months. First-line CAPTEM treatment appeared more effective, with a median PFS of 16.1 months and a median OS of 105.8 months (median PFS 16.1, 7.9, and 9.6 months in first-, second- and ≥third-line respectively, P = .01; with median OS values of 105.8, 47.2, and 24.1 months, respectively, P = .003) In terms of ORR, the first-line treatment again performed better, resulting in an ORR of 54.7% compared to 33.3% and 30.0% in the second and third or higher lines, respectively (P < .001). Grade 3-4 side effects occurred only in 22.5% of the patients, leading to a discontinuation rate of 9.5%. Despite the differences in outcomes based on treatment line, we did not observe a significant difference in terms of side effects between the first and subsequent lines of treatment.The substantial superior outcomes in patients receiving first-line CAPTEM treatment highlight its potential as an effective treatment strategy for patients with metastatic NET.© The Author(s) 2023. Published by Oxford University Press.